<code id='B9A75B3E79'></code><style id='B9A75B3E79'></style>
    • <acronym id='B9A75B3E79'></acronym>
      <center id='B9A75B3E79'><center id='B9A75B3E79'><tfoot id='B9A75B3E79'></tfoot></center><abbr id='B9A75B3E79'><dir id='B9A75B3E79'><tfoot id='B9A75B3E79'></tfoot><noframes id='B9A75B3E79'>

    • <optgroup id='B9A75B3E79'><strike id='B9A75B3E79'><sup id='B9A75B3E79'></sup></strike><code id='B9A75B3E79'></code></optgroup>
        1. <b id='B9A75B3E79'><label id='B9A75B3E79'><select id='B9A75B3E79'><dt id='B9A75B3E79'><span id='B9A75B3E79'></span></dt></select></label></b><u id='B9A75B3E79'></u>
          <i id='B9A75B3E79'><strike id='B9A75B3E79'><tt id='B9A75B3E79'><pre id='B9A75B3E79'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:focus    Page View:591
          Adobe

          Venture firms backing health tech startups are telegraphing cautious optimism for 2024, advising startups to expect smaller and fewer checks as well as possible market consolidation but not to abandon hope just yet as investments stabilize following a sharp drop-off.

          As customers — often health systems, payers, or employers — and backers plot how they’ll invest shrinking budgets, they’re increasingly savvy about metrics, investors told STAT. They’re also less interested in rapid growth, and more keen on startups that can demonstrate savings and efficiency.

          advertisement

          That’s a sharp contrast from the unrestrained health tech investments that peaked in 2021, fueled by a pandemic-era frenzy for virtual appointments, mental health care and app-based therapies.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Peter Hotez and the public health issue of online harassment
          Peter Hotez and the public health issue of online harassment

          AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

          read more
          Eisai exec who led development of Alzheimer’s drug to retire
          Eisai exec who led development of Alzheimer’s drug to retire

          IvanCheungisretiringaschairmanofEisai'sU.S.operationsandglobalheadofitsAlzheimer’sdiseaseunit.Chanta

          read more
          Peter Hotez and the public health issue of online harassment
          Peter Hotez and the public health issue of online harassment

          AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

          read more

          Cancer, immunology, HIV research ensnared in fetal tissue politics

          MollyFergusonforSTATScientistsattheUniversityofWisconsin-Madisonhavespentyearstryingtounravelthedeta